genOway | ULTIMATE PREDICTABILITY

genO-hSA/hFcRn (scan or click)

DOUBLE HUMANIZED genO-hSA/hFcRn MOUSE MODEL

Double humanized genO-hSA/hFcRn mouse model as a cutting-edge platform for preclinical development of hSA (hALB) and FcRn-oriented therapeutics

APPLICATIONS

genO-hSA/hFcRn drives advances across **immuno-oncology**, **infectious diseases** and **autoimmunity**:

- Assess **pharmacokinetics and pharmacodynamics (PK/PD)** features, including biodistribution and binding affinity
- Screen compounds based on **extended half-life**
- Assess the **efficacy** of optimized therapeutics such as Fc-engineered antibodies, constructs fused to hSA, hSA- and/or FcRn-binding proteins or small molecules

MODEL USED BY

argenx · Avacta · Crescendo biologics · CROWN BIOSCIENCE · GSK · novozymes · TONIX PHARMACEUTICALS



MODEL FEATURES

- Physiological expression and distribution of hSA and human FcRn
- Lack of expression of the murine target genes
- Higher physiological affinity of human serum albumin to human FcRn
- Unaltered blood chemistry compared to a wild-type mouse

ORDERS, DELIVERY & CARE

- Orders are made directly with genOway; breeding, housing and delivery are outsourced
- Breeding facilities in the US and Europe through our trusted partners:

TACONIC BIOSCIENCES · charles river


- Quick, compliant, and reliable door-to-door delivery worldwide at your facility or at the CRO of your choice
- Models with certified **SOPF** health status from **AAALAC-accredited** and **PHS-assured** professional breeders

genOway | ULTIMATE PREDICTABILITY


genO-hSA/hFcRn (scan or click)

SELECTED VALIDATION DATA


More data available on our website or upon request




Expression of hFcRn is physiological in genO-hSA/hFcRn mice novozymes



Half-life of drugs conjugated to human albumin is significantly extended in genO-hSA/hFcRn mice



Correlation analysis of the half-life of 4 ADCs in genO-hSA/hFcRn model vs humans or non-human primates (NHP) CROWN BIOSCIENCE



Treatment of genO-hSA/hFcRn mice or NCG mice with CB307, a bispecific antibody targeting PSMA and CD137, shows an extended serum half-life of CB307 in genO-hSA/hFcRn mice Crescendo biologics

KEY PUBLICATIONS

GSK

In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders
Vantourout JC et al., 2021 - Bioconjug Chem

Crescendo biologics

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Archer et al., 2024 - Clin Cancer Res

argenx

Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin
Ma et al., 2024 - JCI Insight

novozymes

Generation of a double transgenic humanised neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs
Viuff et al., 2015 - J Control Release

RELATED MODELS

genO-hFcγR/hFcRn	genO-hTFRC/hSA/hFcRn	genO-hSA/hFcRn/hIgG1	genO-hSA/hFcRn/Rag1KO
genO-hFcγR/hSA/hFcRn	genO-panhCD3/hSA/hFcRn	genO-hSA/hFcRn/hIgG1/hIgκ	genO-hFcγR/hFcRn/VISTA

For more information

Visit the genO-hSA/hFcRn page

For further inquiries

Contact Us